l e t t e r s lysed K562/CD19 cells (K562 erythroleukemia cells transduced with a lentiviral vector encoding the human CD19 gene) and Raji-ffluc (Raji lymphoma cells transduced with a lentiviral vector encoding the FFLuc-eGFP fusion gene) as efficiently as T cells expressing the CD19-Hi CAR, and did not recognize control K562/ROR1 cells (K562 cells transduced with a lentiviral vector encoding the human ROR1 gene) ( Fig. 1b) . CD19-specific recognition by Strep-tag II CAR-T cells was confirmed by the production of interleukin 2 (IL-2) and interferon (IFN)-γ after co-culture with CD19 + tumor cells ( Fig. 1c) . We then investigated whether Strep-tag II could be introduced into a TCR specific for the breast cancer antigen NY-BR-1 (ref. 10) . Strep-tag II TCRs were expressed in primary CD8 + T cells as determined by staining with anti-Strep-tag mAb or human leukocyte antigen (HLA) tetramer, and conferred equivalent function as the introduction of the wild-type NY-BR-1 TCR (Supplementary Fig. 1b-f) . These data indicate that inclusion of Strep-tag II did not interfere with CAR or TCR expression or in vitro function.
The length and composition of the spacer between the scFv and the T-cell membrane can affect CAR-T cell recognition 8 . CD19 CAR-T cells with short (IgG4 hinge), intermediate (hinge-C H 3) and long (hinge-C H 2-C H 3) spacers lysed CD19 + tumor cells in vitro; however, the short spacer CAR (CD19-Hi) resulted in higher cytokine production ( Supplementary Fig. 2a ). A hierarchy of cytokine production and T-cell proliferation was also observed for CAR-T cells containing one, two or three Strep-tag II sequences between the scFv and IgG4 hinge, and was independent of the co-stimulatory domain (4-1BB or CD28) in the CAR (Supplementary Fig. 2b,c) . The CD19 CAR with one Strep-tag II contained 19 additional amino acids in the spacer compared with the CD19-Hi CAR, yet conferred significantly (P < 0.05) greater cytokine production and cell proliferation after tumor recognition, suggesting that the incorporation of Strep-tag II and Gly/Ser sequences into CAR design could optimize spacer length and/or add flexibility to improve signaling ( Supplementary Fig. 2b-d) .
We evaluated the in vivo antitumor activity of CD19 Strep-tag II CAR-T cells in cohorts of NSG (non-obese diabetic (NOD)/severe combined immune deficient (SCID)/IL-2rγ (null)) mice engrafted with Raji lymphoma. Mice treated with T cells transduced with the CD19-Hi CAR, or with CD19 CARs containing one or three Strep-tag II sequences in the spacer region had complete tumor elimination in <28 d, but tumors progressed in mice treated with control T cells ( Fig. 1d) . Staining with anti-EGFRt and anti-Strep-tag II was used to track CAR-T cells in blood samples obtained after the T-cell infusion (Fig. 1e) ,
Adoptive immunotherapy with genetically engineered T cells has the potential to treat cancer and other diseases. The introduction of Strep-tag II sequences into specific sites in synthetic chimeric antigen receptors or natural T-cell receptors of diverse specificities provides engineered T cells with a marker for identification and rapid purification, a method for tailoring spacer length of chimeric receptors for optimal function, and a functional element for selective antibodycoated, microbead-driven, large-scale expansion. These receptor designs facilitate cGMP manufacturing of pure populations of engineered T cells for adoptive T-cell therapies and enable in vivo tracking and retrieval of transferred cells for downstream research applications.
Adoptive transfer of chimeric antigen receptor (CAR)-and T-cell receptor (TCR)-engineered T cells has shown striking efficacy for the treatment of particular human malignancies [1] [2] [3] [4] [5] . Current approaches administer cell products comprising a mixture of transduced and nontransduced T cells, and expression of introduced receptors on T cells is variable. Ideally, engineered receptors would be designed to facilitate purification or selective expansion of receptor-bearing T cells and enable their in vivo tracking and reisolation for functional analysis.
Here we design such multifunctional receptors through incorporation of modified Strep-tag II sequences at various locations in the extracellular region of the CAR or TCR (Strep-tag CAR; Strep-tag TCR) 6 . We selected Strep-tag II to evaluate as a receptor-intrinsic marker because binding reagents for Strep-tag are used in clinical cell processing 7 .
We introduced one or more Strep-tag II sequences with Gly/Ser linkers at the N terminus, between the VL and VH, or between the single-chain Fv (scFv) and the hinge of CD19 CARs with 4-1BB/CD3ζ or CD28/CD3ζ signaling domains ( Supplementary Fig. 1a ) 8 . The constructs were encoded in lentiviral vectors with truncated epidermal growth factor receptor (EGFRt) downstream of a T2A sequence to provide an independent transduction marker 9 . CD19-Hi, a conventional CD19-CAR without Strep-tag II, served as a control for functional assays (Supplementary Fig. 1a ). We transduced human CD8 + T cells, sorted for EGFRt expression and evaluated CAR surface expression by staining with an anti-Strep-tag II monoclonal antibody (mAb). All Strep-tag CAR-T cells were stained with anti-Strep-tag II mAb, independent of the position or number of Strep-tag II sequences, and staining intensity was highest for CAR-T cells that contained three Strep-tag II sequences ( Fig. 1a) . All the Strep-tag II CAR-T cells l e t t e r s and a time-course analysis of CAR-T cells in blood demonstrated that the Strep-tag II and CD19-Hi CAR-T cells proliferated and contracted similarly during tumor elimination ( Fig. 1f) .
We speculated that anti-Strep-tag II mAbs could be used to isolate CAR-expressing T cells from blood after transfer to evaluate changes in their gene expression in vivo. We sorted CAR-T cells with the npg l e t t e r s anti-Strep-tag II mAb or anti-EGFRt mAb to >95% purity from Raji tumor-bearing NSG mice and from NSG mice that were not engrafted with Raji lymphoma but received Strep-tag II CAR-T cells, and cytokine gene expression was determined using the Qiagen (Hilden, Germany) Human Common Cytokines PCR Array. IFN-γ, IL-2 and tumor necrosis factor (TNF)-α were markedly upregulated in CAR-T cells from tumor-bearing compared to nontumor-bearing mice ( Fig. 1g) , consistent with elevated levels of these cytokines in the serum of patients with B-cell malignancies treated with CD19 CAR-T cells.
We also observed upregulation of granulocyte-macrophage colonystimulating factor (GM-CSF), IL-13 and IL-5, which we confirmed in supernatants of CAR-T cells stimulated with Raji tumor cells in vitro ( Fig. 1g,h) . To ensure that anti-Strep-tag II mAb could be similarly used to detect CAR-T cells in human blood, we spiked peripheral blood mononuclear cells (PBMCs) and whole blood with CAR-T cells and found that the T cells were readily detected by anti-Strep-tag II mAb staining (Supplementary Fig. 3a-c) . Thus, Strep-tag II labeling can be used to track CAR-T cells and analyze their gene expression in vivo during an antitumor immune response. Anti-CD3/CD28 mAb-coated beads are used to nonselectively activate T cells and facilitate transduction with viral vectors, but at the same time induce proliferation of both transduced and nontransduced T cells 11, 12 . We hypothesized that multivalent binding of Strep-tag II would selectively activate CAR signaling and induce proliferation only of transduced T cells. Co-culture of Strep-tag II CAR and control CAR-T cells with microbeads coated with anti-Strep-tag II mAb alone or combined with anti-CD28 mAb induced CD25 upregulation only in Strep-tag II CAR-T cells (Fig. 2a) , and expanded CD4 and CD8 Strep-tag II CAR-T cells >100-fold in 9 d of culture ( Fig. 2b) . Activation and proliferation was independent of scFv specificity and costimulatory domains in the CAR (Supplementary Fig. 4a-c) . The frequency of Strep-tag II CAR-T cells increased from ~26-33% to 84-92% in cultures stimulated with anti-Strep-tag II/CD28 beads, but did not increase in cultures with IL-2 alone (Fig. 2c) . Analysis of TCR diversity of CAR-T cells before and after expansion with anti-Strep-tag II/CD28 showed that a diverse repertoire was retained, and the expanded T cells expressed CD62L, CD28 and CD27, maintained CAR-directed cytolytic function, and proliferated in response to tumor cells ( Supplementary  Fig. 5a-d) . CAR-T cells expanded with anti-Strep-tag II/CD28 stimulation were as effective in eliminating Raji lymphoma in NSG mice as those expanded with anti-CD3/CD28 mAbs ( Fig. 2d) . Receptor tyrosine kinase-like orphan receptor-1 (ROR1)-specific CAR-T cells expanded with anti-Strep-tag II/CD28 also retained function in vitro, and in vivo against ROR1 + MDA − MB-231 breast cancer xenografts in NSG mice, demonstrating that this approach can be applied broadly in CAR-T cell therapy (Supplementary Fig. 6a-c) .
Strep-tag II CAR-T cells could be expanded 1 × 10 6 -fold by repeated stimulation with anti-Strep-tag II/CD28 beads every 9-12 d for l e t t e r s applications where large numbers of T cells are necessary. Expanded T cells continued to express the CAR, CD62L and CD28 and retained specificity for CD19 + targets after three stimulations, albeit with a decrease in cytokine production after the second stimulation ( Supplementary Fig. 7a-d) .
The ideal manufacturing process for T-cell therapy would rapidly generate pure cell products for patient administration. Current procedures for obtaining CAR-T cells require 10-20 d of culture, and provide cell products with a variable proportion of transduced cells 1, 2, 13 . The high binding affinity of Strep-tag II for StrepTactin suggested that StrepTactin-coated beads might be used as a simple strategy for rapid selection of Strep-tag II-expressing CAR-T cells. d-biotin, which has even higher affinity for StrepTactin could then be used to elute enriched Strep-tag CAR-T cells. We examined whether Strep-tag CAR-T cells could be selected using an automated device (T-CATCH/IBA), in which agarose beads were functionalized with αCD3/CD28 stimulation npg l e t t e r s immobilized StrepTactin and loaded into plastic tips. After washing to remove unbound T cells, Strep-tag CAR-T cells were released from the beads by the addition of d-biotin. Strep-tag CAR-T cells containing two or three Strep-tag II sequences were enriched from 26-28% to >90% purity, with yields of 40-60% (Fig. 3a,b) . T cells transduced with the Strep-tag II NY-BR-1 TCR with two Strep-tag II sequences were also enriched to high purity using StrepTactin beads (data not shown). CAR-T cells containing one Strep-tag II were not enriched, perhaps because the affinity of a single Strep-tag II in the CAR was insufficient for stable binding to StrepTactin beads. We then compared in vivo antitumor efficacy of CD19 CAR-T cells containing three Strep-tag II sequences that were enriched 8 d after transduction with the T-CATCH device with that of CAR-T cells selected using an anti-EGFR mAb, and either directly transferred to mice or cultured to remove the bound anti-EGFRmAb (Fig. 3c) . T-CATCH-enriched T cells were of comparable purity to T cells sorted using anti-EGFRmAb (Fig. 3d) , and eliminated Raji tumors in all mice. In contrast, CAR-T cells sorted with anti-EGFR mAb did not eliminate Raji tumors (Fig. 3e) , their survival in vivo was compromised ( Fig. 3f) and additional in vitro culture was required for optimal efficacy (Fig. 3e-g) .
A theoretical disadvantage of including Strep-tag II in the CAR that could be evaluated in immunodeficient mice is that, in addition to the mouse scFv and fusion sites, the foreign Strep-tag II sequences could elicit T-cell and/or humoral immune responses. Humoral immunity can be examined only by in vivo studies in immunocompetent hosts; however, to address the issue of T-cell immunogenicity, we screened the Strep-tag II, linker and candidate flanking sequences in the CAR before construction of vectors using NetMHC3.4 to identify HLA-binding peptides. We did not identify sequences likely to bind to common HLA class I alleles with high affinity. Collectively, our studies show that the addition of Strep-tag II provides a receptorintrinsic surface marker that endows engineered T cells with multiple functionalities, facilitating cost-effective and efficient current good manufacturing practice (cGMP), in vivo monitoring and analysis of therapeutic cell products in clinical applications.
MeThods
Methods and any associated references are available in the online version of the paper. 
oNLINe MeThods
Vector construction and preparation of viral vectors. CD19 and ROR1specific CARs were constructed as previously described 14 . Spacer domains consisted of either a short (12 aa) IgG4 hinge, intermediate (119 aa) IgG4 hinge-C H 3 or a long (229 aa) IgG4 hinge-C H 2-C H 3 domain as described 8 .
Strep-tag II CARs were designed by incorporating one or more copies of 9 aa Strep-tag II (NWSHPQFEK) fused with a Gly/Ser (G4S)2 linker N-terminal to the scFv, between VL and VH, or N-terminal to the hinge region. All Strep-tag II CARs used the short IgG4 hinge fused to human CD28 transmembrane domain and to a signaling module derived from either CD28 or 4-1BB and the cytoplasmic domain of CD3ζ as described 14 . The construct encoded a T2A sequence and a truncated epidermal growth factor receptor (EGFRt) sequence downstream of the CAR 9 .
Codon-optimized nucleotide sequences encoding each transgene were synthesized (Life Technologies; IDT DNA Technologies) or generated by overlap extension PCR and cloned into the epHIV7 lentiviral vector 15 . CD19 and ROR1 CAR lentivirus supernatants were produced in 293T cells co-transfected with each of the lentiviral vector plasmids and the packaging vectors pCHGP-2, pCMV-Rev2 and pCMV-G using CalPhos transfection reagent (Clontech). Medium was changed 12 h after transfection, and lentivirus collected after 24, 48 and 72 h.
The NY-BR-1 TCR was derived from a T-cell clone isolated from a healthy donor as described 10 . The sequences of the variable regions of the TCR chains were determined by sequencing 3′-RACE-PCR products and then combined with constant regions containing modifications to increase TCR expression and stability 16, 17 . The TCR-chains were linked by a P2A element, codonoptimized (Life Technologies), and cloned into the retroviral vector MP71 (ref. 18 ). To generate a Strep-tag II containing TCR, two Strep-tag sequences were included at the N terminus of the TCRα-chain 19 . Virus supernatant was generated as described 18 .
Transduction of T cells with CAR lentiviral and TCR retroviral vectors.
Blood samples were obtained from donors who provided written informed consent for research protocols approved by the Institutional Review Board of the Fred Hutchinson Cancer Research Center and peripheral blood mononuclear cells were prepared by Ficoll-Hypaque gradient centrifugation. CD8 + and CD4 + T cells were isolated from PBMC using CD8 + or CD4 + T Cell Isolation Kits (Miltenyi Biotec), activated with anti-CD3/CD28 beads (Life Technologies) according to the manufacturer's instructions, transduced on day 1 or 3 after activation by exposure to lentiviral supernatant supplemented with 0.8 µg/ml polybrene (Millipore), and centrifuged at 800g for 45 min at 32 °C. T cells were transduced with retrovirus as described before 18 . T cells were expanded in RPMI, 10% human serum, 2 mM l-glutamine, 1% penicillinstreptomycin and 50 µM β-mercaptoethanol (CTL medium), supplemented with recombinant human IL-2 to a final concentration of 50 U/ml. Aliquots of transduced CAR-T cells were stained with biotin-conjugated anti-EGFR antibody and streptavidin-PE (Miltenyi), and EGFRt-positive T cells were sorted on a FACS-Aria II (Becton Dickinson). After sorting, CD19 CAR-T cells were expanded for some experiments by stimulation with irradiated (8,000 rad) CD19 + B-lymphoblastoid cell line cells (LCL) at a T cell/LCL ratio of 1:7 in CTL supplemented with 30-50 U/ml IL-2 for another 8~10 d to remove the residual-bound antibody. R12 CAR-T cells after EGFRt sort and NY-BR-1 TCR-transduced T cells after Vβ22 sort, were expanded using a rapid expansion protocol (REP) as described 20 .
Flow cytometric analysis. Conjugated antibodies specific for CD4, CD8, CD25, CD137, CD45, CD62L, CD27, CD28 (BD Biosciences), Strep-tag II (Genscript), EGFR (ImClone Systems) and Vβ22 (Beckman Coulter) were used for staining analysis by flow cytometry. Biotinylated antibodies were stained with streptavidin-PE (BD Biosciences, San Jose, CA). T cells transduced with the NY-BR-1 TCR were analyzed by flow cytometry after staining with antibodies specific for CD8, Strep-tag II, Vβ22 and major histocompatibility complex (MHC)-tetramers loaded with NY-BR-1 peptide (FHCRC Immune Monitoring Lab). Staining with propidium iodide (PI, BD Biosciences) was used for live/dead cell discrimination as directed by the manufacturer. Flow analyses were done on a FACS Canto II (Becton Dickinson, Franklin Lakes, NJ). Data were analyzed using FlowJo software (Treestar).
Chromium release, cytokine secretion and CFSE proliferation assays. Target cells were labeled with Cr 51 (PerkinElmer) for 2 h, washed and incubated in triplicates at 1 × 10 3 cells/well with effector T cells at various effector/target (E:T) ratios for 4 h of culture. Specific lysis was determined using the standard formula. For analysis of cytokine secretion, target and effector cells were plated in triplicate wells at an E:T ratio of 2:1 (Raji, peptide-pulsed T2 cells) or 4:1 (K562/CD19 and K562/ROR1), and cytokine production was measured in supernatants removed after 24 h incubation by multiplex cytokine immunoassay (Luminex) or enzyme-linked immunosorbent assay (ELISA). For analysis of proliferation, the T cells were labeled with 0.2 µM carboxy fluorescein succinimidyl ester (CFSE, Invitrogen), washed and plated in triplicate wells with stimulator cells at a ratio of 2:1 (Raji, peptide-pulsed T2 cells and MDA-MB231) or 4:1 (K562/CD19 and K562/ROR1) in CTL medium without exogenous cytokines. After 5 d of incubation, the cells were labeled with anti-CD8 or CD4 mAb and PI to exclude dead cells from analysis. Samples were analyzed by flow cytometry for cell division of live T cells determined by dilution of CFSE.
Generation of anti-Strep-tag mAb and bead stimulation of Strep-tag CAR-T cells.
An anti-Strep-tag II mAb was raised in the FHCRC Antibody Development Core by immunizing BALB/c mice with the NWSHPQFEK peptide conjugated to KLH using the Maleimide Activated BSA/KLH Conjugation Kit (Sigma, MBK-I). Spleen cells from immunized mice were fused with mouse myeloma cells, and supernatants from hybridomas screened by ELISA on a BSA conjugate of the above peptide, and by flow cytometric analysis on Strep-tag and control CAR-T cells. One clone termed 3E8, which secretes an lgG2b antibody was selected based on its affinity to Strep-tag II.
An optimized concentration of anti-Strep-tag II mAb (150 µg) alone or with anti-CD28 mAb (50 µg) was covalently coated on 50-mg customized functional magnetic beads (3.0~3.9 µm) according to product manual (Spherotech) 12 . For activation and expansion of Strep-tag CAR-T cells, anti-Strep-tag II mAb-coated microbeads were added to T cells in CTL medium supplemented with IL-2 (50 U/ml) alone or plus IL-15 (2 ng/ml). During T-cell expansion, culture medium was changed every 3 d.
Enrichment of Strep-tag II CAR-T cells using StrepTactin-coated resin. T cells containing various proportions of Strep-tag II CAR-T cells were washed
with IS buffer (IBA) and aliquoted into multiple wells of the Tip-based Cell Affinity Chromatograph (T-CATCH) (IBA) device that selects cells based on binding to nonmagnetic resin with immobilized StrepTactin on the surface and is preloaded into sterile plastic tips. Sample loading, cell selection, washing and elution are performed automatically using computer-controlled preformatted software. T cells bound to the resin were released from the tips using IS buffer with 50 µM d-biotin and residual bound T cells were flushed out from the tips using IS buffer. The selected T cells were washed twice with PBS with 0.5% human serum before assaying for purity and in vitro and in vivo function.
Adoptive transfer of T cells in NOD/SCID/γc −/− (NSG) mice engrafted with
Raji-ffluc or MDA-MB231-ffluc cells. The FHCRC Institutional Animal Care and Use Committee approved all mouse experiments. 6-to 8-week-old female NSG mice were obtained from the Jackson Laboratory or bred in-house. Mice were injected intravenously (i.v.) with 0.5 × 10 6 Raji-ffluc tumor cells through the tail vein, and received injections of CAR-modified or control T cells i.v. 7 d after tumor inoculation.
MDA-MB231 breast cancer xenografts were established in NSG mice by injecting 5 × 10 5 ROR1 + MDA-MB231-ffluc cells subcutaneously (s.c.). Mice received i.v. injections of CAR-modified or control T cells 7 d after tumor inoculation. Tumor progression and distribution were evaluated by serial bioluminescence imaging as described 14 . All the animal experiments were repeated at least once. Five mice were used in each experimental group to provide 81% power to detect an effect size of 1.75, based on a t-test with a one-sided 0.05 level of significance. RT 2 profiler human common cytokine PCR array. The cytokine profile of CD19-1ST/4-1BB/CD3ζ CAR-T cells in vivo was examined 2 d after adoptive transfer into NSG mice (n = 3) with and without Raji-ffluc tumor cell xenografts using the Human Common Cytokines PCR Array, which profiles npg the expression of 84 human cytokine genes (SABiosciences, Frederick, MD). CD19 CAR-T cells were sorted from blood, bone marrow and spleen using anti-Strep-tag II or EGFR mAb staining, RNA was extracted using RNeasy Plus Mini Kit (QIAGEN) and cDNA was synthesized using RT 2 First Strand Kits (QIAGEN). The PCR array was performed according to the manufacturer's protocol for the ABI7900HT Sequence Detection System (Applied Biosystems, Foster City, CA). The PCR data were analyzed using Qiagen PCR Array Data Analysis Software (Excel & Web based). For each PCR reaction, the samples were run in triplicates, data were normalized to five housekeeping genes average C t values, and a mean fold-change (2-∆∆ CT ) and s.d. were calculated to examine the gene upregulation in the CAR-T cells infused into NSG mice previously engrafted with Raji tumor cells compared to CAR-T cells infused into NSG mice that were not inoculated with Raji tumor cells. Only genes with C t values <35 in T cells from the tumor-bearing mice were selected to focus the comparison on abundant or moderately abundant target mRNAs.
TCR sequencing. Strep-tag II CAR-T cells were sorted with anti-Strep-tag II mAb and an aliquot was submitted to TCRB repertoire analysis using the ImmunoSeq Assay 21,22 (Adaptive Biotechnologies). A second aliquot was expanded on anti-Strep-tag II/CD28-microbeads and then submitted for TCRB repertoire analysis. TCR clonotypes at a frequency of > 0.01% were used to conduct overlap analysis and Pearson product-moment correlation coefficient (Pearson's r) was calculated to measure linear correlation between two cell products.
Statistical analyses.
Statistical analyses were conducted using Prism Software (GraphPad). Student's t-test was conducted as a two-sided paired test with a confidence interval of 95% and results with a P value less than 0.05 were considered significant.
Antibodies. CD45-FITC (BD Pharmagen; Cat: 555482); CD8-PE-Cy7 (BD Pharmagen; Cat: 557746); CD4-APC (BD Pharmagen; Cat: 555349); Strep-tag II Antibody (biotin) (Genscript: Cat: A10737); CD28-PE-Cy7 (BioLegend; Cat: 302925); CD27-PE (eBioscience; Cat: 12-0279); CD62L-APC-Cy7
